Active compound combinations
AssigneeBayer Aktiengesellschaft
InventorsAgostinos Michael Klüken, Julie Geist, Cyril Montagne, Anthony Millet, Lionel Nicolas, Tomoki Tsuchiya
Life of this patent
Estimating the term…
Abstract
The present invention relates to active compound combinations, in particular within a fungicide composition, which comprise as compound (A) a compound of formula (I) and as compound (B) a further fungicidally active compound as specified below. Moreover, the invention relates to compositions comprising such compound combination and to the use of the compound combinations and the fungicide compositions as biologically active agent, especially for control of phytopathogenic fungi in crop protection and in the protection of industrial materials and as plant growth regulators.
Claims13
An active compound combination comprising
- (A) at least one compound selected from the group consisting of (I-052) rac-3-[3-(3-cyclopropyl-2-fluorophenoxy)-6-methylpyridazin-4-yl]-5-[(2,4-dimethylphenyl)methyl]-5,6-dihydro-4H-1,2,4-oxadiazine, (I-130) (5S)-3-[3-(3-cyclopropyl-2-fluorophenoxy)-6-methylpyridazin-4-yl]-5-(2,4-dimethylbenzyl)-5,6-dihydro-4H-1,2,4-oxadiazine, (I-300) rac-5-[(4-bromo-2-methylphenyl)methyl]-3-[3-(3-chloro-2-fluorophenoxy)-6-methylpyridazin-4-yl]-5,6-dihydro-4H-1,2,4-oxadiazine, (I-302) rac-3-[3-(3-chloro-2-fluorophenoxy)-6-methylpyridazin-4-yl]-5-[(2-chloro-4-methylphenyl)methyl]-5,6-dihydro-4H-1,2,4-oxadiazine, (I-337) (5S)-5-[(4-bromo-2-methylphenyl)methyl]-3-[3-(3-chloro-2-fluorophenoxy)-6-methyl-pyridazin-4-yl]-5,6-dihydro-4H-1,2,4-oxadiazine, (I-338) (5R)-3-[3-(3-chloro-2-fluorophenoxy)-6-methylpyridazin-4-yl]-5-(2-chloro-4-methylbenzyl)-5,6-dihydro-4H-1,2,4-oxadiazine and (I-339) (5S)-3-[3-(3-chloro-2-fluorophenoxy)-6-methyl-pyridazin-4-yl]-5-(2-chloro-4-methylbenzyl)-5,6-dihydro-4H-1,2,4-oxadiazine,
- and
- (B) at least one further active compound selected from the group consisting of (1.002) difenoconazole, (1.018) prothioconazole, (1.020) spiroxamine, (1.021) tebuconazole, (1.055) mefentrifluconazole, (1.062) fluoxytioconazole, (1.067) N′-(2,5-dimethyl-4-{3-[(1,1,2,2-tetrafluoroethyl)sulfanyl]phenoxy}phenyl)-N-ethyl-N-methyl-imido-formamide, (2.002) bixafen, (2.005) fluopyram, (2.028) inpyrfluxam, (2.038) isoflucypram, (3.020) trifloxystrobin, (3.025) fenpicoxamid, (5.003) captan, (5.010) dithianon, (5.012) folpet, (5.013) mancozeb, (5.018) propineb, (6.002) isotianil, (7.005) pyrimethanil, (13.001) fludioxonil, (13.004) proquinazid, (13.005) quinoxyfen, (15.012) fosetyl-aluminium, (15.016) metrafenone, (15.043) fluoxa¬piprolin and (15.064) (N′-[2-chloro-4-(2-fluorophenoxy)-5-methylphenyl]-N-ethyl-N-methylimidoformamide), (17.001) Bacillus subtilis strain QST713/AQ713 having NRRL Accession No. B-21661 (17.012) a Paenibacillus sp. strain having Accession No. NRRL B-50972 or Accession No. NRRL B-67129 and (18.001) a composition comprising one or more fatty acids or derivatives thereof selected from unsaturated and saturated C12-C24 fatty acids, salts thereof, esters thereof or mixtures of any of the foregoing, wherein at least 95% of said fatty acids or derivatives thereof are in the range of C14 to C20.
Dependencies are inferred from the claim text.